Rapt Therapeutics Inc Expected To Post A Loss Of 13 Cents A Share: Earnings Preview

Rapt Therapeutics

05/05/2025 15:06

RAPT Therapeutics Inc RAPT.OQ RAPT.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for RAPT Therapeutics Inc is for a loss of 13 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 1.1% in the last three months. ​

Wall Street's median 12-month price target for RAPT Therapeutics Inc is $4.00​, above​ its last closing price of $0.97. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.31
-0.37
-1.14
Missed
-206.5
Sep. 30 2024
-0.57
-0.56
-0.47
Beat
16.7
Jun. 30 2024
-0.72
-0.72
-0.71
Beat
1.4​
Mar. 31 2024
-0.80
-0.81
-0.79
Beat
2.3
​​Dec. 31 2023
-0.86
-0.86
-0.80
Beat
6.8
Sep. 30 2023
-0.75
-0.75
-0.82
Missed
-8.9​
Jun. 30 2023
-0.79
-0.78
-0.66
Beat
15.6
Mar. 31 2023
-0.67
-0.68
-0.76
Missed
-11.8

This summary was machine generated May 5 at 14:06 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)